Home › Funds › Elevate Capital Advisors, LLC › ROIV
Elevate Capital Advisors, LLC position in ROIV
ROIVANT SCIENCES LTD · Health Care
Elevate Capital Advisors, LLC reported holding 25,331 shares of ROIV (ROIVANT SCIENCES LTD) in its Q3 2026 13F filing — a position valued at US$926K, representing 0.54% of its reported portfolio and ranking #43 among its reported holdings. Elevate Capital Advisors, LLC has disclosed ROIV holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-03 · Source: SEC EDGAR Form 13F-HR
How Elevate Capital Advisors, LLC's ROIV position evolved
Elevate Capital Advisors, LLC first disclosed a stake in ROIV in Q4 2024 at 178,853 shares (US$2.1M). Across 8 filings, Elevate Capital Advisors, LLC increased the stake 1 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 25,331 shares valued at US$926K — an increase of 336 shares quarter over quarter.. Notable position changes include a 35% trim in Q2 2025 (shares rose 34% over the following quarter), a 32% trim in Q4 2025 (shares rose 28% over the following quarter), a 59% trim in Q1 2026 (shares rose 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 178.85K | $2.12M | New |
| Q1 2025 | 177.39K | $1.79M | Reduce |
| Q2 2025 | 116.03K | $1.31M | Reduce |
| Q3 2025 | 113.78K | $1.72M | Reduce |
| Q4 2025 | 77.55K | $1.68M | Reduce |
| Q1 2026 | 32.15K | $890.55K | Reduce |
| Q2 2026 | 25.00K | $884.57K | Reduce |
| Q3 2026 | 25.33K | $926.34K | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ROIV and 13F data
ROIV (ROIVANT SCIENCES LTD) is a Health Care company. 64 other funds we track also report a position in ROIV — the largest reported positions include QVT Financial LP (US$839.6M), Farallon Capital Management (US$506.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$506.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ROIV
- QVT Financial LP 23.72M sh · $839.56M · Q2 2026
- Farallon Capital Management 14.31M sh · $506.40M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 14.31M sh · $506.40M · Q2 2026
- ADAGE CAPITAL PARTNERS GP, L.L.C. 10.35M sh · $366.26M · Q2 2026
- PERCEPTIVE ADVISORS LLC 8.09M sh · $286.14M · Q2 2026
- Patient Square Capital LP 8.02M sh · $283.86M · Q2 2026
- Darwin Global Management, Ltd. 6.75M sh · $234.33M · Q2 2026
- Rubric Capital Management LP 6.00M sh · $212.34M · Q2 2026
- BAKER BROS. ADVISORS LP 4.72M sh · $166.93M · Q2 2026
- Affinity Asset Advisors, LLC 3.75M sh · $132.71M · Q2 2026
- ADAR1 Capital Management, LLC 3.16M sh · $111.73M · Q2 2026
- Maverick Capital 2.83M sh · $100.12M · Q2 2026
More on Elevate Capital Advisors, LLC
FAQ
How long has Elevate Capital Advisors, LLC held ROIV?
Elevate Capital Advisors, LLC has disclosed ROIV holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Elevate Capital Advisors, LLC's current position in ROIV?
As of Q3 2026, Elevate Capital Advisors, LLC holds 25.33K shares of ROIV (ROIVANT SCIENCES LTD), valued at $926.34K, representing 0.54% of its reported portfolio and ranking #43.
Has Elevate Capital Advisors, LLC been buying or selling ROIV?
In the latest 13F filing (Q3 2026), Elevate Capital Advisors, LLC increased its position in ROIV.
Which other funds hold ROIV?
Other major institutional holders of ROIV include QVT Financial LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.